GLP1s and Osteoarthritis
Newly published research explores the link between Osteoarthritis and GLP1s -- positive results that are somewhat predictable.
Latest
Viking Therapeutic's new GLP1 impresses at ObesityWeek 2024
At ObesityWeek 2024, Viking Therapeutic showed study results on their new drug VK2735 -- 8% body weight loss at 28 days, in the highest dose.
Semaglutide's link to blinding disease (NAION)
We explore the link between blinding disease/vision loss and Semaglutide, as reported by medical research.
Patent expirations for GLP1 Receptor Agonists
How long will we have to wait for generic versions of GLP1 drugs? We take a look at patent expiry dates for the most popular brands & GLP1 formulations.
FDA reconsidering Tirzepatide shortage list removal
After legal action by a group of compounders, the FDA is reviewing their removal of Tirzepatide (Mounjaro, Zepbound) from the shortage list.
Compounders sue FDA over Tirzepatide shortage changes
Compounders sue FDA for removing Eli Lilly's weight loss drug from the shortage list. Does the case have legs?
Why the Tirzepatide shortage ending might be bad news.
Bad news that sounds like good news: FDA ends shortage Eli Lilly's GLP-1 (Tirzepatide). We'll tell you why that's bad news.
GLP1s and Sleep Apnea
GLP1s (in particular Tirzepatide, created by Eli Lilly) have positive effects on Sleep Apnea
Habener, Mosjov and Knudsen win the Lasker award
The current GLP1 receptor agonist boom was made possible by the work of Joel Habener, Lotte Bjerre Knudsen, and Svetlana Mojsov.
Insurers continue to embrace Virtual Healthcare for GLP1s
Omada is moving from virtual health into the wider field of wellness programs, enhancing their offering. We dig into what's changed.
Novo's CEO will testify, but change is unlikely
Novo's CEO goes to congress to testify, but not much is likely to change in the drug's pricing. We dive into some historical context.
Reminder: Ozempic face isn't real
Ozempic face isn't real -- fast weight loss causes changes to the skin, and your face is a prime area that will change.
Amgen's GLP1: MariTide (formerly AMG-133)
Amgen is working on a new GLP1, entering the race -- AM-133. We dig into the trials and research and see if it's got any promise.
Eli Lilly's other new GLP1 - Orforglipron
Eli Lilly is developing new GLP1 drugs, and Orforglipron is one of them. It's not easy to pronounce, but it is easy to take, and easy to produce.
GLP1 reverses diabetes in human cells (in mice)
Scientists managed to increase the number of insulin-producing cells in a human-cell-in-mouse experiment.
Thyroid issues with GLP1?
Do GLP1 Receptor Agonists (Ozempic, Wegovy, Mounjaro, Zepbound, and others) cause thyroid issues?
includes:study
Are GLP1 side effects all the same?
Do some GLP1s have less negative side effects? They work the same, but can affect you differently -- let's look at the research.
category:news
23andMe gets into GLP1
23andMe leaves drug discovery, but embraces providing GLP1 Receptor Agonists -- emphasizing a shift to active preventative care.
includes:review
Systematic reviews of GLP1 worth reading
Want to get refreshed on GLP1 research into drugs like Ozempic, Wegovy, Mounjaro, Zepbound and others? Start here.
drug:amycretin
Novo's new GLP1: Amycretin
Novo has a new drug it's working on -- Amycretin. Amycretin is a dual agonist, with the *new* agonist being Amylin. Read more about it here.
category:news
GLP1's effect on ADHD
What effects does GLP1 have on ADHD? It's early, but we take a look at some published research.
categeory:watercooler
Life before GLP1s: Topiramate
Wondering what the world was doing before GLP1s? We discuss Topiramate, a popular appetite suppressant.
category:news
A new GLP1: Retatrutide
Is mimicking more hormones better? Let's find out -- the new GLP1 drug Retatrutide is a *triple* receptor agonist
category:news
Are GLP1s primarily brain drugs?
Are GLP1 Receptor Agonists (Ozempic, Wegovy, Mounjaro, etc) primarily brain drugs?
company:eli-lilly
Eli Lilly China approval and new suppliers
As the race to manufacture more GLP1 medications intensifies, Eli Lilly gets approval in China and more suppliers.
chemical:semaglutide
24% Less kidney disease risk with Semaglutide (Ozempic)
Can we trust research funded by Novo Nordisk which found a 24% decrease in kidney disease risk for people on Semaglutide (Ozempic)?
categeory:watercooler
How much are people actually paying for GLP1s?
We dive deep into the reports of people's GLP1 costs -- how much is the average person paying for Ozempic, Wegovy, Mounjaro, Zepbound and others?
drug:danuglipron
Pfizer's GLP1: Danuglipron
Read more about Dangulipron, Pfizer's GLP1 receptor agonist. Will it be better than Ozempic, Wegovy, Mounjaro, Zepbound and others?
Teneligliptin is for T2D, not weight loss
The name isn't easy to read (or say), but the results stand out – Teneligliptin is a drug used for type 2 diabetes that does not seem to correlate well to weight loss in general, unlike GLP1 agonists. 🍃Don't know what a GLP1 Receptor Agonist is, or how drugs like Ozempic,
drug:ozempic
Semaglutide (Ozempic) vs Tirzepatide (Mounjaro)
Learn the major differences between Ozempic (Semaglutide) and Mounjaro (Tirzepatide)
Reduced weight and heart benefits for women on Ozempic
A recent study showed that women can lose
categeory:watercooler
What people get wrong about Ozempic
We debunk some common misconceptions about GLP1 drugs like Ozempic, Wegovy, Mounjaro and others.